After 25 years of drug development, do we know JAK?

RMD Open. 2022 Jul;8(2):e002409. doi: 10.1136/rmdopen-2022-002409.

Authors

Mahta Mortezavi¹, David A Martin², Hendrik Schulze-Koops³

Affiliations

¹ Inflammation and Immunology, Pfizer Inc, New York, New York, USA Mahta.mortezavi@pfizer.com.
² Inflammation and Immunology, Pfizer Inc, Cambridge, Massachusetts, USA.
³ Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany.

No abstract available

Keywords: Antirheumatic Agents; Arthritis, Rheumatoid; Pharmacokinetics; Therapeutics.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Drug Development
Humans

Substances

Antirheumatic Agents